ClinicalTrials.gg
RecruitingNCT06704516Updated Jan 13, 2025

COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study

A Phase 1 interventional study of Menopausal hormone therapy in Menopause and Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by University of Oxford · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford — 1 open to participants now, 3 under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · University of Oxford.

Started
2025
the only one that year
Phase 1
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford, this one is the only one that started in 2025, is one of 2 in phase 1, and was the 10th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

1 of the 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford, or all of them as a file.
02

Study summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide, currently affecting approximately 1-in-4 people globally. The prevalence is expected to rise further, driven at least partly by the epidemic of obesity and diabetes. MASLD is a condition of fat build-up in the liver that can progress to liver scarring which is associated with higher chances of death. Women are more than twice as likely to develop MASLD after menopause compared to before menopause, and previous research has shown that this may be caused by a lack of oestrogen. A lack of oestrogen is also believed to lead to harmful changes in adipose (body fat), which has an important role in the development of MASLD. Oestrogen contained in hormone replacement therapy (HRT) is an effective treatment for hot flushes and other problems in menopause. The popularity of HRT has increased dramatically in the United Kingdom in recent years, however the exact way in which it affects adipose and MASLD is unclear. The investigators will study how HRT affects the processes that drive MASLD in 10 women before and after using the treatment. This is a small-scale pilot study to understand feasibility of recruitment and test the procedures for a future, larger-scale studies.

The investigators will recruit women who are about to begin HRT for the first time and perform the same tests for each participant before starting HRT, and after using HRT for 12-weeks. The participants will undergo meal testing including non-radioactive, stable isotopes, and blood and breath samples will be collected to measure fat processing. The total fat content of the liver will be measured using magnetic resonance imaging (MRI) scans. Adipose samples will be collected, fat metabolites will be measured and the distribution of fat around the body will be assessed using a dual energy x-ray absorptiometry (DEXA) scan. To find out how HRT affects these processes, the results from before and after using HRT will be compared. Understanding how HRT affects adipose and the liver may help reduce the development of MASLD in women after the menopause and improve their health and survival.

03

Conditions studied

  • Menopause
  • Metabolic Dysfunction Associated Steatotic Liver Disease

Keywords

  • hormone
  • MASLD
  • NAFLD
  • liver
  • estrogen
  • replacement
  • adipose
  • oestrogen
  • fat
  • MASH
  • steatosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Potential participant is willing and able to give for participation in the trial
  • In the Investigator's opinion, is able and willing to comply with all trial requirements
  • Female, aged 18 years and above
  • 18 to 45 kg/m2
  • status:

    • For women ≥ 40 defined clinically (amenorrhoea for ≥ 1 year) or biochemically (FSH >30IU/L on 2 occasions 4-6 weeks apart).
    • For women \< 40 defined as a combination of oligomenorrhoea/amenorrhoea for ≥ 4 months and FSH >30IU/L on 2 occasions 4-6 weeks apart
    • Women who have undergone bilateral oophorectomy (no additional testing is required)
  • Low oestradiol levels
  • No exposure to systemic oestrogen-based HRT within the previous 3 months
  • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.

Exclusion criteria

Exclusion Criteria:

  • Potential participant with known chronic liver disease, with the exception of MASLD
  • The use of drugs which, in the opinion of the investigator, will significantly impact on hepatic lipid content or metabolism. This applies to drugs currently being used or used in the past, within a timeframe where the investigator believes it may impact hepatic lipid content or metabolism.
  • Potential participant with any other medical explanation for amenorrhoea, apart from menopause
  • History of harmful alcohol consumption (>35 units/week) or alcohol misuse disorder
  • Potential participants with to MRI
  • Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
  • Potential participant with of less than 6 months.
  • Potential participants who have participated in another research trial involving an product in the past 12 weeks.
  • Potential participants without a sufficient understanding of written or verbal English to participate in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Hormone Replacement Therapy

    Participants starting any brand, composition, route and dose of oestrogen-based systemic hormone replacement therapy, will be included in this group.

    Drug: Menopausal hormone therapy

Interventions

  • DrugMenopausal hormone therapy

    Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen. Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)

06

What researchers measure

Primary outcomes

  1. Recruitment into an experimental medicine study investigating the impact of HRT on MASLD

    Number of participants who are screened and recruited into the study

    Time frame: 7 months

Secondary outcomes

  1. Acceptability of experimental protocols in experimental medicine study investigating the impact of HRT on MASLD

    Feedback from questionnaire completed by study participants

    Time frame: From enrollment to the end of the study after completing 12 weeks of intervention

  2. Participant retention in an experimental medicine study investigating the impact of HRT on MASLD

    Number of participants who complete the study (per protocol)

    Time frame: From enrollment to the end of the study after completing 12 weeks of intervention

  3. Fatty acid esterification into triglyceride

    Measurement of 13C-palmitate incorporation into very low density lipoprotein triglyceride (VLDL-TG)

    Time frame: Performed at baseline and after 12 weeks of intervention

  4. Hepatic lipid content

    Measurement of intrahepatic triglyceride content by magnetic resonance imaging / spectroscopy

    Time frame: At baseline and after 12 weeks of intervention

  5. Whole body fatty acid oxidation

    Measurement of incorporation of 13C into breath CO2 using GC-C-IRMS.

    Time frame: At baseline and after 12 weeks of intervention

  6. Fasting and postprandial plasma intrahepatic fatty acid synthesis.

    Change in hepatic fatty acid synthesis as measured by incorporation of 2H2 palmitate (via 2H2O) into VLDL-TG

    Time frame: At baseline and after 12 weeks of intervention

  7. Liver profile blood tests and circulating lipid profiles

    Routine laboratory biochemistry

    Time frame: At baseline and after 12 weeks of intervention

  8. Interstitial levels of metabolites in adipose tissue

    Change in adipose tissue metabolite profile

    Time frame: At baseline and after 12 weeks of intervention

  9. Adipose tissue transcriptomic profile

    Change in adipose tissue transcriptomic profile in abdominal subcutaneous and gluteal depots

    Time frame: At baseline and after 12 weeks of intervention

  10. Total and regional lean and fat tissue distribution

    Total and regional lean and fat mass on Dual energy X-ray absorptiometry (DXA) scan

    Time frame: At baseline and after 12 weeks of intervention

Other outcomes

  1. Adipose tissue steroid profile

    Adipose tissue steroid profile

    Time frame: At baseline and after 12 weeks of intervention

07

Study locations

1 of 1 sites recruiting
  • Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM), Churchill Hospital
    Oxford, Oxfordshire OX3 7LE, United Kingdom
    Recruiting
    • Jiawen Dong, MB BChir, MRCP · Contactjiawen.dong@ocdem.ox.ac.uk · +441865 857300
    • Jeremy Tomlinson, MB BCh, PhD, FRCP · Contact
    • Jiawen Dong, MB BChir, MRCP · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Aug 2025, 7 months later.

Of 125 phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 26, 2024
StartEst.
Jan 2025
Primary completionEst.
Aug 5, 2025
CompletionEst.
Jan 1, 2026
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704516
Collaborators
Oxford University Hospitals NHS Trust
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Jan 2025 (estimated)
Primary completion
Aug 5, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Jan 13, 2025

Study contacts

Jiawen Dong, MB BChir, MRCP
Contact
jiawen.dong@ocdem.ox.ac.uk
+441865 857300

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion